Boston – October 27, 2026 -- People living with Friedreich's ataxia (FA) have a new gene therapy candidate heading toward human testing: Solid Biosciences says the FDA has cleared its Investigational New Drug (IND) application for SGT-212, with a Phase 1b trial planned for the second half of 2025.

SGT-212 attacks FA through two delivery routes

The company describes SGT-212 as the first gene therapy in the industry to use a dual route of administration. It delivers full-length frataxin protein in two ways:

United States – October 27, 2026 -- Solid Biosciences has dosed 40 participants with its Duchenne gene therapy SGT-003 and reported positive interim safety and biomarker data from the ongoing Phase 1/2 INSPIRE DUCHENNE trial. The company presented the update at the 2026 MDA Clinical & Scientific Conference.

McLean, Virginia – October 27, 2026 -- Hilton Honors members with Silver, Gold, Diamond or Diamond Reserve status can now use their Points toward hotel charges straight from their phone, with no front desk visit. The new Pay with Points benefit is live at 150 participating hotels in the U.S.

United States – October 27, 2026 -- Solid Biosciences has expanded its INSPIRE DUCHENNE gene therapy trial to 43 participants and now accepts children aged 4 to under 12, up from the previous range of 4 to under 8.

Three participants dosed with no serious adverse events

INSPIRE DUCHENNE is a first-in-human, multicenter, Phase 1/2 open-label study. It tests the safety, tolerability and efficacy of a single intravenous infusion of SGT-003, a next-generation AAV gene therapy candidate, in ambulant boys with Duchenne.

United States – October 27, 2026 -- Families affected by Duchenne muscular dystrophy have early data on SGT-003, an investigational gene therapy from Solid Biosciences: 90 days after dosing, three boys showed average microdystrophin expression of 110%.

Keller, Texas – October 27, 2026 -- Homeowners in Northeast Tarrant County can now call one licensed company for both a water heater and a furnace, as Polly Plumbing, Heating & Air adds heating and air conditioning service ahead of North Texas' first freeze.

The National Weather Service puts the average first freeze for Dallas-Fort Worth on November 22, which is 26 days away. NOAA's 2026-2027 Winter Outlook, released October 15, calls for a very strong El Niño and wetter-than-average conditions across the southern United States from December through February.

United States – October 27, 2026 -- Fifteen people with Duchenne muscular dystrophy had received the investigational gene therapy SGT-003 in the INSPIRE DUCHENNE clinical study as of August 12, 2025, according to developer Solid Biosciences.

Ten trial sites span four countries

The multi-center, open-label trial now runs 10 active clinical sites in the United States, Canada, Italy, and the United Kingdom. More sites are expected to open later this year.

United States – October 27, 2026 -- Solid Biosciences has dosed 33 children aged 1 to 10 with its investigational gene therapy SGT-003 for Duchenne muscular dystrophy, and a Phase 3 trial has enrolled its first patient.

United States – October 27, 2026 -- Parents have more sway over teen drinking than many assume: 74% of teens say their parents are the biggest influence on whether they drink alcohol. Mothers Against Drunk Driving (MADD) built its Power of Parents program around that finding, with conversation tools for caregivers.

United States – October 27, 2026 -- Choosing a designated driver before anyone starts drinking is the most cost-effective way to get home safely, and the stakes are high: drunk-driving crashes in the U.S. kill one person every 44 minutes.

People skip the plan for familiar reasons. They don't want to leave the car overnight, they want to avoid the cost or wait of a rideshare, or they simply don't feel impaired. But alcohol affects the same judgment you would use to assess your ability to drive, so the call is harder to make accurately in the moment.